Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/tissue-engineering.md — the filesystem corpus, unchanged. Not an edit.
12.7 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["bodies"]categories: ["bodies"]tags: ["regenerative medicine", "scaffolds", "biomaterials", "stem cells", "transplantation", "cartilage"]tags: ["regenerative medicine", "scaffolds", "biomaterials", "stem cells", "transplantation", "cartilage"]summary: "The construction of living tissue from cells, scaffolds and signalling molecules, a field with approved products for skin and cartilage but no solid organ after three decades."summary: "The construction of living tissue from cells, scaffolds and signalling molecules, a field with approved products for skin and cartilage but no solid organ after three decades."updated: "2026-07-27"updated: "2026-10-29"humanEvidence: "Approved products treat burns, chronic wounds, focal knee cartilage defects, corneal burns and congenital athymia in patients; the only organ-like construct with years of human follow-up is a small bladder series."humanEvidence: "Approved products treat burns, chronic wounds, focal knee cartilage defects, corneal burns and congenital athymia in patients; the only organ-like construct with years of human follow-up is a small bladder series."access: "Skin substitutes, chondrocyte implantation, limbal grafts and cultured thymus tissue are approved and delivered through specialist centres; no engineered solid organ is available at any price."access: "Skin substitutes, chondrocyte implantation, limbal grafts and cultured thymus tissue are approved and delivered through specialist centres; no engineered solid organ is available at any price."reversibility: "difficult"reversibility: "difficult"lines 30–44 → 30–4415 unchanged lines not shown
}}`````` **Tissue engineering** is the construction of functional living tissue by combining cells, a supporting scaffold and biochemical or mechanical signals, either in a bioreactor before implantation or inside the body afterwards. The term was fixed by a 1993 *Science* article by Robert Langer and Joseph Vacanti that set out the field's programme and its founding triad.[^langer1993] Three decades later the discipline has delivered approved treatments for skin, cartilage, cornea and thymus, and none for a kidney, liver or heart. The distance between those two lists is the field's defining fact.**Tissue engineering** is the construction of functional living tissue by combining cells, a supporting scaffold and biochemical or mechanical signals, either in a bioreactor before implantation or inside the body afterwards. The term was fixed by a 1993 *Science* article by Robert Langer and Joseph Vacanti that set out the field's programme and its founding triad.[^langer1993] Three decades later the discipline has delivered approved treatments for skin, cartilage, cornea and thymus, but none for a kidney, liver or heart. ## The triad## The triad The classical formulation has three components.The classical formulation has three components. **Cells** provide the biological function. They may be autologous — taken from the patient, expanded in culture, and returned, which avoids rejection but takes weeks and cannot be stockpiled — or allogeneic, which allows an off-the-shelf product but usually requires immunosuppression or immune-privileged siting. Increasingly they are derived from [[induced-pluripotent-stem-cells]], which decouples supply from donor tissue at the cost of differentiation and safety work.**Cells** provide the biological function. Autologous cells are taken from the patient, expanded in culture and returned; they avoid rejection but take weeks to prepare and cannot be stockpiled. Allogeneic cells allow an off-the-shelf product but usually require immunosuppression or immune-privileged siting. Increasingly they are derived from [[induced-pluripotent-stem-cells]], which decouples supply from donor tissue at the cost of differentiation and safety work. **Scaffold** provides shape, mechanical support and a surface for attachment. Early scaffolds were synthetic polyesters already approved as resorbable sutures: polyglycolic acid, polylactic acid, their copolymers, and polycaprolactone. These degrade by hydrolysis on a tunable timescale, ideally matched to the rate at which cells lay down their own matrix. Natural scaffolds — collagen, fibrin, silk, and stripped donor tissue as described in [[decellularized-scaffolds]] — trade manufacturing control for better biological cues.**Scaffold** provides shape, mechanical support and a surface for attachment. Early scaffolds were synthetic polyesters already approved as resorbable sutures: polyglycolic acid, polylactic acid, their copolymers, and polycaprolactone. These degrade by hydrolysis on a tunable timescale, ideally matched to the rate at which cells lay down their own matrix. Natural scaffolds, such as collagen, fibrin, silk and the stripped donor tissue described in [[decellularized-scaffolds]], trade manufacturing control for better biological cues. **Signals** are the growth factors, matrix stiffness, oxygen tension and mechanical loading that tell cells what to become. A scaffold seeded with chondrocytes and left static produces poor cartilage; the same construct under cyclic compression in a bioreactor produces better cartilage. Mechanical conditioning turned out to be as important as any molecule.**Signals** are the growth factors, matrix stiffness, oxygen tension and mechanical loading that tell cells what to become. A scaffold seeded with chondrocytes and left static produces poor cartilage; the same construct under cyclic compression in a bioreactor produces better cartilage. Mechanical conditioning turned out to be as important as any molecule. lines 50–61 → 50–615 unchanged lines not shown
{ "year": "1988", "title": "The term enters use", "text": "A National Science Foundation workshop popularises 'tissue engineering' as a name for the emerging combination of biomaterials and cell biology." }, { "year": "1988", "title": "The term enters use", "text": "A National Science Foundation workshop popularises 'tissue engineering' as a name for the emerging combination of biomaterials and cell biology." }, { "year": "1993", "title": "The programme stated", "text": "Langer and Vacanti's Science article sets out cells-plus-scaffold-plus-signals as a general strategy for replacing lost tissue, and is taken as the field's founding document." }, { "year": "1993", "title": "The programme stated", "text": "Langer and Vacanti's Science article sets out cells-plus-scaffold-plus-signals as a general strategy for replacing lost tissue, and is taken as the field's founding document." }, { "year": "1997", "title": "The ear mouse", "text": "Charles Vacanti's group grows human-ear-shaped cartilage on a polymer scaffold implanted under the skin of an athymic mouse. The image travels far beyond the science it represents." }, { "year": "1997", "title": "The ear mouse", "text": "Charles Vacanti's group grows human-ear-shaped cartilage on a polymer scaffold implanted under the skin of an athymic mouse. The image travels far beyond the science it represents." }, { "year": "1997–2001", "title": "First approvals", "text": "Autologous chondrocyte implantation and engineered skin substitutes reach the market, followed within a few years by the commercial collapse of several of their manufacturers." }, { "year": "1997-2001", "title": "First approvals", "text": "Autologous chondrocyte implantation and engineered skin substitutes reach the market, followed within a few years by the commercial collapse of several of their manufacturers." }, { "year": "2006", "title": "Engineered bladders", "text": "Anthony Atala's group reports autologous bladder constructs implanted in seven young patients with spina bifida, the first engineered organ-like structure followed for years in humans." } { "year": "2006", "title": "Engineered bladders", "text": "Anthony Atala's group reports autologous bladder constructs implanted in seven young patients with spina bifida, the first engineered organ-like structure followed for years in humans." }]]`````` The ear mouse deserves separate mention because it shaped public expectation more than any result in the field. The construct was cartilage — avascular, mechanically simple, immunologically quiet — grown in an immunodeficient animal that could not reject it. It demonstrated that a polymer scaffold could hold a complex shape while cells filled it in. It demonstrated nothing about vascularized organs, and it was read as though it had.The ear mouse deserves separate mention because it shaped public expectation more than any result in the field. The construct was cartilage, a tissue that is avascular, mechanically simple and immunologically quiet, and it was grown in an immunodeficient animal that could not reject it. It showed that a polymer scaffold could hold a complex shape while cells filled it in. It showed nothing about vascularized organs, though it was read as if it had. ## What reached the clinic## What reached the clinic lines 63–69 → 63–691 unchanged line not shown
Cultured epidermal autografts have been used for massive burns since the 1980s. Bilayered skin substitutes combining allogeneic fibroblasts and keratinocytes on a collagen or polymer matrix are approved for chronic wounds; they act largely as living dressings that release growth factors rather than as permanent grafts. Autologous chondrocyte implantation, first approved in the United States in 1997 and superseded by a matrix-associated version in 2016, treats focal cartilage defects in the knee. Cultured limbal stem cell grafts for corneal burns received European approval in 2015. Allogeneic cultured thymus tissue for children born without a thymus was approved in the United States in 2021, and is one of the few products that reconstitutes an organ's function rather than patching a surface.Cultured epidermal autografts have been used for massive burns since the 1980s. Bilayered skin substitutes combining allogeneic fibroblasts and keratinocytes on a collagen or polymer matrix are approved for chronic wounds; they act largely as living dressings that release growth factors rather than as permanent grafts. Autologous chondrocyte implantation, first approved in the United States in 1997 and superseded by a matrix-associated version in 2016, treats focal cartilage defects in the knee. Cultured limbal stem cell grafts for corneal burns received European approval in 2015. Allogeneic cultured thymus tissue for children born without a thymus was approved in the United States in 2021, and is one of the few products that reconstitutes an organ's function rather than patching a surface. Atala's bladder work remains the most ambitious result with long human follow-up: autologous urothelial and muscle cells seeded on a biodegradable scaffold and implanted, with functional improvement sustained over years in a small cohort.[^atala2006] The attempt to commercialize it failed, as did several contemporaneous ventures. The commercial failures were not primarily scientific. Autologous products are closer to a service than a manufactured good, with a batch size of one, a cold chain, and a reimbursement code that often does not exist. This is the gap between laboratory validation and operational use that [[technology-readiness-level]] describes, and it determines pricing and therefore the questions raised in [[access-and-inequality]].Atala's bladder work remains the most ambitious result with long human follow-up: autologous urothelial and muscle cells seeded on a biodegradable scaffold and implanted, with functional improvement sustained over years in a small cohort.[^atala2006] The attempt to commercialize it failed, as did several contemporaneous ventures, and the reasons were mostly not scientific. Autologous products are closer to a service than a manufactured good, with a batch size of one, a cold chain, and a reimbursement code that often does not exist. This is the gap between laboratory validation and operational use that [[technology-readiness-level]] describes, and it determines pricing and therefore the questions raised in [[access-and-inequality]]. > [!key] Why the simple tissues worked> [!key] Why the simple tissues worked> Every clinically successful engineered tissue is one where oxygen can diffuse from surrounding host tissue to every cell. That single physical constraint, not regulatory caution or funding, separates the products that exist from the ones that do not.> Every clinically successful engineered tissue is one where oxygen can diffuse from surrounding host tissue to every cell. That single physical constraint, not regulatory caution or funding, separates the products that exist from the ones that do not.lines 72–96 → 72–982 unchanged lines not shown
Four obstacles have proved durable.Four obstacles have proved durable. **Vascularization.** A construct thicker than roughly a millimetre needs its own blood supply. Building a capillary bed remains unsolved, whether by printing it, as in [[organ-bioprinting]], by reusing a donor organ's vascular tree, or by relying on host angiogenesis, which grows in at roughly a fraction of a millimetre per day — too slow for a thick construct.**Vascularization.** A construct thicker than roughly a millimetre needs its own blood supply. Building a capillary bed remains unsolved, whether by printing it, as in [[organ-bioprinting]], by reusing a donor organ's vascular tree, or by relying on host angiogenesis. Host vessels grow in at roughly a fraction of a millimetre per day, too slow for a thick construct. **Cell number and phenotype.** A liver contains on the order of a hundred billion cells, and primary hepatocytes dedifferentiate within days outside the body. Producing enough cells of the right type, in the right state, remains a manufacturing problem as much as a biological one.**Cell number and phenotype.** A liver contains on the order of a hundred billion cells, and primary hepatocytes dedifferentiate within days outside the body. Producing enough cells of the right type, in the right state, remains a manufacturing problem as much as a biological one. **Maturation.** Stem-cell-derived tissue is fetal-like. Cardiomyocytes contract weakly, neurons are electrically immature, and no reliable protocol drives them to adult phenotype on a useful timescale. The same ceiling limits [[organoids]]. Cells taken from an elderly recipient bring a second problem, the functional decline catalogued under [[stem-cell-exhaustion]], which is part of why several groups have proposed combining autologous cell manufacture with [[epigenetic-reprogramming]] to restore proliferative capacity before use.**Maturation.** Stem-cell-derived tissue is fetal-like. Cardiomyocytes contract weakly, neurons are electrically immature, and no reliable protocol drives them to adult phenotype on a useful timescale. The same ceiling limits [[organoids]]. Cells taken from an elderly recipient bring a second problem, the functional decline catalogued under [[stem-cell-exhaustion]], which is part of why several groups have proposed combining autologous cell manufacture with [[epigenetic-reprogramming]] to restore proliferative capacity before use. **Integration.** An implanted construct must connect to host vasculature, innervation, and in some cases a duct or lumen, and must survive the host's foreign-body response. Work by Jennifer Elisseeff's group showed, in a mouse muscle-injury model, that biomaterial scaffolds elicit a type 2 immune response involving T cells that determines whether the outcome is regeneration or fibrosis, reframing the immune system as an active participant in the repair rather than an obstacle to be suppressed. The same dependence has not been demonstrated in humans.[^sadtler2016]**Integration.** An implanted construct must connect to host vasculature, innervation, and in some cases a duct or lumen, and must survive the host's foreign-body response. Work by Jennifer Elisseeff's group showed, in a mouse muscle-injury model, that biomaterial scaffolds elicit a type 2 immune response involving T cells, and that this response determines whether the outcome is regeneration or fibrosis. The work recast the immune system as an active participant in repair rather than an obstacle to be suppressed. The same dependence has not been demonstrated in humans.[^sadtler2016] ## Current directions## Current directions The field's centre of gravity has shifted in three ways. First, away from the pre-fabricated construct and toward *in vivo* tissue engineering, where an acellular material recruits the patient's own cells and the body serves as the bioreactor; most commercially successful regenerative products now work this way. Second, toward immunomodulatory design, in which the scaffold's job is to steer macrophage and T-cell behaviour rather than merely to provide shape. Third, toward biofabrication methods that give spatial control, including printing, moulding of tissue building blocks, and assembly of organoid units into larger structures.The field has shifted in three directions. The first is away from the pre-fabricated construct and toward *in vivo* tissue engineering, where an acellular material recruits the patient's own cells and the body serves as the bioreactor; most commercially successful regenerative products now work this way. The second is toward immunomodulatory design, in which the scaffold's job is to steer macrophage and T-cell behaviour rather than merely to provide shape. The third is toward biofabrication methods that give spatial control, including printing, moulding of tissue building blocks, and assembly of organoid units into larger structures. Two adjacent products show how the boundary of the field has moved. Engineered cardiac patches are being developed as an adjunct to, not a replacement for, the mechanical circulatory support described in [[artificial-heart]]. Cultured red cells, discussed in [[artificial-blood]], are an engineered tissue in everything but name, and face a manufacturing problem of scale rather than architecture.Two adjacent products show how the boundary of the field has moved. Engineered cardiac patches are being developed as an adjunct to, not a replacement for, the mechanical circulatory support described in [[artificial-heart]]. Cultured red cells, discussed in [[artificial-blood]], are an engineered tissue in everything but name, and face a manufacturing problem of scale rather than architecture. Engineered tissue has also found a market that does not require implantation at all. Liver, cardiac and tumour tissue built on chips or in multiwell formats is used for toxicity screening, and demand grew as regulators moved away from mandatory animal testing for some drug classes — the same shift that names the computational models described in [[human-digital-twins]] among the acceptable alternatives.Engineered tissue has also found a market that does not require implantation at all. Liver, cardiac and tumour tissue built on chips or in multiwell formats is used for toxicity screening, and demand grew as regulators moved away from mandatory animal testing for some drug classes. The same regulatory shift names the computational models described in [[human-digital-twins]] among the acceptable alternatives. ## Outlook## Outlook Tissue engineering is a mature field with a modest clinical footprint and an unmet founding promise. Its practitioners generally no longer forecast a printed kidney; they forecast incremental gains in islet constructs, vascular grafts, nerve conduits, corneal tissue and cardiac patches, each of which is a real clinical need served by a few cubic centimetres of tissue. Whether the discipline ever produces one of the [[lab-grown-organs]] it was founded to deliver depends on the vascular problem, and the strongest current argument is that any answer would come from combining a biologically constructed capillary bed with an engineered large-vessel framework rather than from fabricating either alone. The alternative is to stop building and start inducing, which is why the biology of animals that rebuild structures on their own, covered in [[limb-regeneration]], has drawn renewed attention from engineers. Meanwhile the [[organ-shortage]] is being addressed by [[xenotransplantation]], machine perfusion and donation policy, all of which were considered less likely than engineered organs when the field was named. The same ordering holds in reproductive medicine, where [[uterus-transplantation]] has produced live births while recellularized uterine scaffolds remain in animal work.Tissue engineering is a mature field with a modest clinical footprint and an unmet founding promise. Its practitioners generally no longer forecast a printed kidney; they forecast incremental gains in islet constructs, vascular grafts, nerve conduits, corneal tissue and cardiac patches, each of which is a real clinical need served by a few cubic centimetres of tissue. Whether the discipline ever produces one of the [[lab-grown-organs]] it was founded to deliver depends on the vascular problem, and the strongest current argument is that any answer would come from combining a biologically constructed capillary bed with an engineered large-vessel framework rather than from fabricating either alone. The alternative is to induce regeneration instead of building tissue, which is why the biology of animals that rebuild structures on their own, covered in [[limb-regeneration]], has drawn renewed attention from engineers. Meanwhile the [[organ-shortage]] is being addressed by [[xenotransplantation]], machine perfusion and donation policy, all of which were considered less likely than engineered organs when the field was named. The same ordering holds in reproductive medicine, where [[uterus-transplantation]] has produced live births while recellularized uterine scaffolds remain in animal work. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
99 lines are the same in both revisions, and 45 of them are not shown. Neither revision here is necessarily the current article — read Tissue engineering for the text this wiki stands behind today.